浅部真菌感染中的抗真菌药物治疗进展

摘要/Abstract

关键词: 浅部真菌感染, 新型抗真菌药物, 作用机制, 体外药敏, 临床试验

中图分类号:

R978.5

杨之辉, 李若瑜. 浅部真菌感染中的抗真菌药物治疗进展[J]. 中国真菌学杂志, 2022, 17(4): 339-348.

[1] 廖万清, 顾菊林.深部真菌感染治疗的现状与对策[J].中国感染与化疗杂志, 2007, 7(2):101-103.
[2] 都琳, 杨雅骊, 雷文知, 等.浅部真菌感染的药物治疗[J].世界临床药物, 2014, 35(12):709-714.
[3] BROWN G D, DENNING D W, GOW N A, et al.Hidden killers:human fungal infections[J].Sci Transl Med, 2012, 4(165):165rv13.
[4] KHANNA D, BHARTI S.Luliconazole for the treatment of fungal infections:an evidence-based review[J].Core Evid, 2014, 9:113-124.DOI:10.2147/CE.S49629.eCollection 2014.
[5] DENNING DW, MATTHEW K, SOBEL J D, et al.Global burden of recurrent vulvovaginal candidiasis:a systematic review[J].Lancet Infect Dis, 2018, 18(11):e339-e347.
[6] MERCER D K, O'NEIL D A.Innate inspiration:antifungal peptides and other immunotherapeutics from the host immune response[J].Front Immunol, 2020, 11:2177.DOI:10.3389/fimmu.2020.02177.
[7] BREAK T J, DESAI J V, NATARAJAN M, et al.VT-1161 protects mice against oropharyngeal candidiasis caused by fluconazole-susceptible and -resistant Candida albicans[J].J Antimicrob Chemother, 2018, 73:151-155.DOI:10.1093/jac/dkx352.
[8] SEILER G T, OSTROSKY-ZWECHNER L.Investigational agents for the treatment of resistant yeasts and molds[J].Curr Fungal Infect Rep, 2021:1-12.DOI:10.1007/s12281-021-00419-5.
[9] ELEWSKI B, BRAND S, DEGENHARDT T, et al.A phase II, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail[J].Br J Dermatol, 2021, 184(2):270-280.
[10] BRAND S R, DEGENHARDT T P, PERSON K, et al.A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally-administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis[J].Am J Obstet Gynecol, 2018, 218(6):624.e1-624.e9.DOI:10.1016/j.ajog.2018.03.001.
[11] PASQUALOTTO A C, THIELE K O, GOLDANI L Z.Novel triazole antifungal drugs:focus on isavuconazole, ravuconazole and albaconazole[J].Curr Opin Investig Drugs, 2010, 11(2):165-174.
[12] CAPILLA J, ORTONEDA M, PASTOR F J, et al.In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi[J].Antimicrob Agents Chemother, 2001, 45(9):2635-2637.
[13] GARAU M, PEREIRO M, DEL-PALACIO A.In vitro susceptibilities of Malassezia species to a new triazole, albaconazole (UR-9825), and other antifungal compounds[J].Antimicrob Agents Chemother, 2003, 47(7):2342-2344.
[14] PASQUALOTTOA C, DENNING D W.New and emerging treatments for fungal infections[J].J Antimicrob Chemother, 2008, 61(suppl_1):i19-30.DOI:10.1093/jac/dkm428.
[15] SIGURGEIRSSON B, ROSSEM K V, MALAHIAS S, et al.A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis[J].J Am Acad Dermatol, 2013, 69(3):416-425.
[16] FÁVERO M L D, BONETTI A F, DOMINGOS E L, et al.Oral antifungal therapies for toenail onychomycosis:a systematic review with network meta-analysis toenail mycosis:network meta-analysis[J].J Dermatolog Treat, 2020:1-10.DOI:10.1080/09546634.2020.1729336.
[17] NOGUCHI H, MATSUMOTO T, KIMURA U, et al.Fosravuconazole to treat severe onychomycosis in the elderly[J].J Dermatol, 2021, 48(2):228-231.
[18] WATANABE S, TSUBOUCHI I, OKUBO A.Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis:a multicenter, double-blind, randomized phase III study[J].J Dermatol, 2018, 45(10):1151-1159.
[19] MIYATA A, KIMURA U, NOGUCHI H, et al.Tinea capitis caused by Trichophyton violaceum successfully treated with fosravuconazole[J].J Dermatol, 2021, 48(7):e331-e332.DOI:10.1111/1346-8138.15901.
[20] AZIE N, ANGULO D, DEHN B, et al.Oral ibrexafungerp:an investigational agent for the treatment of vulvovaginal candidiasis[J].Expert Opin Investig Drugs, 2020, 29(9):893-900.
[21] ROMAN M, HERNANDEZ C, BLANCO D, et al.SCY-078 phase 2 study in moderate and severe vulvovaginal candidiasis.The 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)[C].Vienna, Poster P1748, Big Sky, Montana Austria, 2017.
[22] SCHWEBKE J, SORKIN-WELLS V, AZIE N, et al.Oral ibrexafungerp efficacy and safety in the treatment of vulvovaginal candidiasis:a phase 3, randomized, blinded, study vs.placebo (VANISH-303)[J].Am J Obstet Gynecol, 2020, 223(6):964-965.
[23] JALLOW S, GOVENDER N P.Ibrexafungerp:a first-in-class oral triterpenoid glucan synthase inhibitor[J].J Fungi, 2021, 7(3):163.DOI:10.3390/jof7030163.
[24] GINTJEE T J, DONNELLEY M A, Thompson G R.Aspiring antifungals:review of current antifungal pipeline developments[J].J Fungi, 2020, 6(1):28.DOI:10.3390/jof6010028.
[25] THOMPSON III G R, LEWIS P, MUDGE S, et al.Open-label crossover oral bioequivalence pharmacokinetics comparison for a 3-day loading dose regimen and 15-day steady-state administration of SUBA-itraconazole and conventional itraconazole capsules in healthy adults[J].Antimicrob Agents Chemother, 2020, 64(8):e00400-20.DOI:10.1128/AAC.00400-20.
[26] ABUHELWA A Y, FOSTER D J R, MUDGE S, et al.Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states[J].Antimicrob Agents Chemother, 2015, 59(9):5681-5696.
[27] LINDSAY J, MUDGE S, THOMPSON G R.Effects of food and omeprazole on novel formulation SUBA-itraconazole in healthy subjects[J].Antimicrob Agents Chemother, 2018, 62(12):e01723-18.DOI:10.1128/AAC.01723-18.
[28] SKIPPER C, ATUKUNDA M, STADELMAN A, et al.Phase I EnACT trial of the safety and tolerability of a novel oral formulation of amphotericin B[J].Antimicrob Agents Chemother, 2020, 64(10):e00838-20.DOI:10.1128/AAC.00838-20.
[29] KIBATHI L, KUMAR P, LIONAKIS M, et al.A phase IIa efficacy, safety, tolerability and pharmacokinetic (PK) study of encochleated amphotericin B in patients with mucocutaneous (esophageal, oropharyngeal, vulvovaginal) candidiasis who are refractory or intolerant to standard non-intravenous therapies[J].Open Forum Infect Dis, 2018, 5(Suppl_1):S435-S435.
[30] U.S.National Library of Medicine.ClinicalTrials.gov (NCT02971007):Safety and efficacy of oral encochleated amphotericin B (CAMB/MAT2203) in the treatment of vulvovaginal candidiasis (VVC)[R/OL].https://clinicaltrials.gov/ct2/show/nct02971007.[2021-07-20].
[31] TATSUMI Y, NAGASHIMA M, SHIBANUSHI T, et al.Mechanism of action of efinaconazole, a novel triazole antifungal agent[J].Antimicrob Agents Chemother, 2013, 57(5):2405-2409.
[32] JOSIU W J, TATSUMI Y, SENDA H, et al.Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis[J].Antimicrob Agents Chemother, 2013, 57(4):1610-1616.
[33] REZAEI-MATEHKOLAEI A, KHODAVAISY S, ALSHAHNI M M, et al.In vitro antifungal activity of novel triazole efinaconazole and five comparators against dermatophyte isolates[J].Antimicrob Agents Chemother, 2018, 62(5):e02423-17.DOI:10.1128/AAC.02423-17.
[34] ELEWSKI BE, RICH P, POLLAK R, et al.Efinaconazole 10% solution in the treatment of toenail onychomycosis:two phase III multicenter, randomized, double-blind studies[J].J Am Acad Dermatol, 2013, 68(4):600-608.
[35] EICHENFIELD LF, ELEWSKI B, SUGARMAN J L, et al.Efinaconazole 10% topical solution for the treatment of onychomycosis in pediatric patients:open-label phase 4 study[J].J Am Acad Dermatol, 2021, 84(4):1140-1142.
[36] KOGA H, NANJOH Y, MAKIMURA K, et al.In vitro antifungal activities of luliconazole, a new topical imidazole[J].Med Mycol, 2009, 47(6):640-647.
[37] JERAJANI H, JANAKI C, KUMAR S, et al.Comparative assessment of the efficacy and safety of sertaconazole (2%) cream versus terbinafine cream (1%) versus luliconazole (1%) cream in patients with dermatophytoses:a pilot study[J].Indian J Dermatol, 2013, 58(1):34-38.
[38] JONES T M, JARRATT M T, MENDEZ-MOGUEL I, et al.A randomized, multicenter, double-blind, vehicle-controlled study evaluating the efficacy and safety of luliconazole cream 1% once daily for 7 days in patients aged ≥ 12 years with tinea cruris[J].J Drugs Dermatol, 2014, 13(1):32-38.
[39] WATANABE S, KISHIDA H, OKUBO A.Efficacy and safety of luliconazole 5% nail solution for the treatment of onychomycosis:a multicenter, double-blind, randomized phase III study[J].J Dermatol, 2017, 44(7):753-759.
[40] GOBBATO A A M, BABADÓPULOS T, GOBBATO C A R S, et al.A randomized double-blind, non-inferiority phase II trial, comparing dapaconazole tosylate 2% cream with ketoconazole 2% cream in the treatment of pityriasis versicolor[J].Expert Opin Investig Drugs, 2015, 24(11):1399-1407.
[41] GOBBATO A A M, GOBBATO C A R S, MORENO R A, et al.Dapaconazole versus ketoconazole in the treatment of interdigital tinea pedis[J].Int J Clin Pharmacol Ther, 2018, 56(1):31-33.
[42] MORAES G, TAINAH B, SANTIAGO G, et al.Comparison of dapaconazole with miconazole in the treatment of tinea cruris[J].J Eur Acad Dermatol Venereol, 2018, 33(1):e18-e20.DOI:10.1111/jdv.15116.
[43] MERCER D K, STEWART C S, MILLER L, et al.Improved methods for assessing therapeutic potential of antifungal agents against dermatophytes and their application in the development of NP213, a novel onychomycosis therapy candidate[J].Antimicrob Agents Chemother, 2019, 63(5):e02117-18.DOI:doi:10.1128/AAC.02117-18.
[44] MERCER D K, ROBERTSON JC, MILLER L, et al.NP213(Novexatin^©):A unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile[J].Med Mycol, 2020, 58(8):1064-1072.
[45] VAN-DER-WEERDEN N, HAYES B, MCKENNA J, et al.The plant defensin HXP124 has the potential to be a new safe and effective topical treatment for onychomycosis[C].ISHAM, Poster, 2018.
[46] TAKAHATA S, KUBOTA N, TAKEI-MASUDA N, et al.Mechanism of action of ME1111, a novel antifungal agent for topical treatment of onychomycosis[J].Antimicrob Agents Chemother, 2015, 60(2):873-880.
[47] GHANNOUM M, ISHAM N, LONG L.In vitro antifungal activity of ME1111, a new topical agent for onychomycosis, against clinical isolates of dermatophytes[J].Antimicrob Agents Chemother, 2015, 59(9):5154-5158.
[48] KUBOTA-ISHIDA N, TAKEI-MASUDA N, KANEDA K, et al.In vitro human onychopharmacokinetic and pharmacodynamic analyses of ME1111, a new topical agent for onychomycosis[J].Antimicrob Agents Chemother, 2018, 62(1):e00779-17.DOI:10.1128/AAC.00779-17.
[49] Springer Nature.Drug profile-DBI 001[R/OL].https://adisinsight.springer.com/drugs/8000568382021.[2021-7-16].
[50] Derm Biont.DermBiont releases positive phase 2 data for DBI-001 in tinea pedis, atopic dermatitis[R/OL].https://adisinsight.springer.com/drugs/8000475532021.[2021-7-16].
[51] JOSEPH P M.Quinoline, quinazoline and acridone alkaloids[J].Nat Prod Rep, 2008, 25:166-187.DOI:10.1039/B612168N.
[52] DE OLIVEIRA D B C, SILVA L B, DA-SILVA B V, et al.A new acridone with antifungal properties against Candida spp.and dermatophytes, and antibiofilm activity against C.albicans[J].J Appl Microbiol, 2019, 127(5):1362-1372.
[53] PIPPI B, JOAQUIM A R, LOPES W, et al.8-Hydroxyquinoline-5-sulfonamides are promising antifungal candidates for the topical treatment of dermatomycosis[J].J Appl Microbiol, 2020, 128(4):1038-1049.
[54] MACHADO G, DIEDRICH D, RUARO T C, et al.Quinolines derivatives as promising new antifungal candidates for the treatment of candidiasis and dermatophytosis[J].Braz J Microbiol, 2020, 51(93):1691-1701.

浅部真菌感染中的抗真菌药物治疗进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	郑冬燕, 曹存巍, 李秀楹, 郑艳青, 潘开素, 廖万清. 广西地区隐球菌感染的临床特征、菌种鉴定及体外抗真菌药物敏感性[J]. 中国真菌学杂志, 2022, 17(3): 188-194.
[2]	程颖, 陈丹. 儿童浅部真菌感染的临床分析[J]. 中国真菌学杂志, 2020, 15(5): 288-292.
[3]	阚思玥, 蔡晴, 金云, 陈伟, 胡素泉, 杨连娟, 刘维达. 婴幼儿皮肤黏膜念珠菌病临床特点及其病原菌体外药敏分析[J]. 中国真菌学杂志, 2020, 15(2): 97-100.
[4]	刘洁, 刘晓云, 于波, 胡小平. 85株皮肤癣菌感染的病原菌分析及标准化体外药物敏感性研究[J]. 中国真菌学杂志, 2019, 14(6): 351-356.
[5]	华海康, 赖美玲, 胡仁静, 张海平, 周成龙, 张晓利, 葛小丽. 院内念珠菌血液感染的菌种分布及药敏分析[J]. 中国真菌学杂志, 2018, 13(3): 173-176.
[6]	宋娜娜, 周晓伟, 李筱芳, 刘维达. 甲真菌病外用药的治疗现状及研究进展[J]. 中国真菌学杂志, 2018, 13(3): 184-187.
[7]	刘昱, 阎澜, 姜远英. 新型抗真菌药物研究进展[J]. 中国真菌学杂志, 2018, 13(2): 105-113.
[8]	钱宇, 乔辉, 郑天军, 唐晨豪, 孙佳愉, 刘文洪. 药用真菌抗肿瘤活性及机制的研究进展[J]. 中国真菌学杂志, 2018, 13(2): 124-128.
[9]	卢祥婷, Arun Karki, 黄欣, 赵敬军. 激光治疗甲真菌病的作用机制研究进展[J]. 中国真菌学杂志, 2017, 12(3): 171-174.
[10]	马照成, 冯西恩, 徐瑞彩. 复发性甲真菌病的治疗策略及安全性评估[J]. 中国真菌学杂志, 2016, 11(2): 111-112.
[11]	陈淳, 陈启红, 孙毅, 高露娟, 曾同祥. 低浓度他克莫司与抗真菌药物联合的体外抗真菌效应[J]. 中国真菌学杂志, 2015, 10(4): 207-209.
[12]	中国中西医结合学会皮肤性病学专业委员会. 硝酸益康唑/曲安奈德乳膏临床应用专家共识[J]. 中国真菌学杂志, 2015, 10(4): 234-235.
[13]	吕雪莲, 刘维达. 毛霉与毛霉病-实验室与临床的新挑战(续)[J]. 中国真菌学杂志, 2013, 8(1): 1-5.
[14]	吕雪莲, 刘维达. 毛霉与毛霉病-实验室与临床的新挑战[J]. 中国真菌学杂志, 2012, 7(6): 321-325.
[15]	高露娟, 余进, 李若瑜. 烟曲霉再鉴定、标准化CSP分型及体外药物敏感性[J]. 中国真菌学杂志, 2011, 6(6): 328-331,336.